Embecta (NASDAQ:EMBC) Reaches New 1-Year Low at $10.09

Embecta Corp. (NASDAQ:EMBCGet Free Report)’s stock price reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $10.09 and last traded at $10.16, with a volume of 52977 shares. The stock had previously closed at $10.25.

Embecta Price Performance

The company has a 50-day simple moving average of $13.79 and a 200-day simple moving average of $15.70. The stock has a market cap of $582.13 million, a PE ratio of 10.71 and a beta of 0.73.

Embecta (NASDAQ:EMBCGet Free Report) last announced its quarterly earnings results on Friday, February 9th. The company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.15. Embecta had a negative return on equity of 18.66% and a net margin of 4.93%. The business had revenue of $277.30 million during the quarter, compared to analysts’ expectations of $264.92 million. During the same quarter last year, the business posted $0.93 earnings per share. The business’s revenue for the quarter was up .6% on a year-over-year basis. On average, equities analysts expect that Embecta Corp. will post 2.14 EPS for the current fiscal year.

Embecta Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Wednesday, February 28th were paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 5.93%. The ex-dividend date of this dividend was Tuesday, February 27th. Embecta’s payout ratio is currently 63.16%.

Insider Activity at Embecta

In other Embecta news, Director David F. Melcher purchased 2,000 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were purchased at an average cost of $16.25 per share, with a total value of $32,500.00. Following the purchase, the director now owns 45,080 shares in the company, valued at $732,550. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.28% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Group AG bought a new stake in shares of Embecta in the 3rd quarter worth $806,000. Dimensional Fund Advisors LP acquired a new stake in Embecta in the 3rd quarter valued at approximately $6,513,000. Envestnet Asset Management Inc. acquired a new stake in Embecta in the 3rd quarter valued at approximately $226,000. Nuveen Asset Management LLC acquired a new stake in Embecta in the 3rd quarter valued at approximately $5,254,000. Finally, Renaissance Technologies LLC bought a new position in shares of Embecta during the 3rd quarter worth approximately $3,095,000. Institutional investors and hedge funds own 93.83% of the company’s stock.

Embecta Company Profile

(Get Free Report)

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.

See Also

Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.